Side effects that occurred in more than 2% of people treated with<unk>  in clinical trials and that occurred more frequently than with placebo, included nose and throat irritation, injection site reactions and bruising, flu-like symptoms, urinary tract infection, diarrhea, bronchitis and cough, and muscle pain, soreness, and spasms. There are no available data on use of<unk>  in pregnant women to assess risks to the fetus, nor is there data on use in children.
Alirocumab
Evolocumab
Olaratumab
Ustekinumab
Durvalumab
Emapalumab
Burosumab
Tralokinumab